Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib –final appraisal consultation document
National Institute for Health and Care Excellence - NICE
National Institute for Health and Care Excellence
15 February 2019
This DRAFT guidance recommends brigatinib for treating anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.